Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Longitudinal analysis of structural biomarkers for disease progression in intermediate age-related macular degeneration: a MACUSTAR study report.

Structural biomarkers indicate risk for iAMD progression and may differentiate eyes progressing to GA from eyes progressing to nAMD, and needs to be considered in clinical trial design.

Lukas Goerdt, Danielle Bessaheken, Jan H. Terheyden et al. · 0 citations
Aug 2026

Real-world outcomes after switching to faricimab in treatment-resistant neovascular AMD: Short-term response and 12-month follow-up.

AimsTo assess the efficacy and safety of faricimab in neovascular age-related macular degeneration (nAMD) resistant to anti-VEGF therapies.MethodsThis retrospective study evaluated nAMD patients with persistent fluid despite anti-VEGF treatments (aflibercept or ranibizumab; mean injection interval of 4.63 ± 0.78 weeks)...

Victoria Marechal, F. Amoroso, Sorana Pacurariu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.